Eyes have it: Avalanche Bio inks $640 million-plus Regeneron gene therapy deal
May 06, 2014 at 13:26 PM EDT
Gene therapy company Avalanche Biotechnologies Inc. struck a deal potentially worth more than $640 million with Regeneron Pharmaceuticals Inc...